[Gilead Sciences Q3 2026 Earnings Call] Gilead Lifts 2026 Sales Outlook by $900 Million as HIV Sales Jump 18%, but Flags $1.5 Billion BIKTARVY IRA Hit in 2028
Gilead Sciences raised its 2026 sales forecast by $900M after Q3 revenue grew 13% YoY to $8.3B, driven by 18% HIV sales growth. Non-GAAP EPS rose 3.2% YoY to $2.55. The company flagged a $1.5B revenue hit in 2028 from Medicare price negotiations on BIKTARVY. Management expects HIV revenue growth in 2028 despite the headwind.
How this was made
The 30-second read
Why it matters
The guidance raise suggests continued revenue momentum, yet the $1.5B Medicare pricing headwind could compress margins and affect valuation.
Market read
Investors will reprice Gilead's stock based on the net effect of higher sales outlook versus regulatory cost exposure.
What to watch
Upcoming FDA decisions on oral HIV regimens and CAR‑T therapy could provide additional upside not reflected in the guidance.
Background
Gilead's Q3 earnings are the first release of its 2026 guidance and the first detailed IRA impact disclosure.
Ticker impact
Gilead reported Q3 2026 results, raised full-year sales guidance by $900M and disclosed a $1.5B IRA impact on BIKTARVY revenue in 2028.
mixed pressure as investors weigh higher sales guidance against the $1.5B Medicare pricing headwind.
Strong quarter and raised guidance are bullish, but the disclosed regulatory cost is material and may weigh on the stock.
Market effects
Highlights potential IRA pricing pressure on other HIV/rare disease biotech firms.
U.S. biotech sector may see modest volatility as investors reassess Medicare pricing risk.
Limited to companies with similar Medicare exposure; broader market impact minimal.
Counterpoint
The IRA hit may be overstated; Gilead's diversified pipeline could offset the cost, supporting a buy.
Key entities
- CompanyGilead Sciences
US‑listed biopharma reporting earnings and guidance.
- ProductBIKTARVY
Flagship HIV therapy subject to Medicare price negotiation.
